AAV-Mediated NPHP5 Gene Therapy for Retinal Preservation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for NPHP5-related Leber congenital amaurosis (LCA) are ineffective, unsafe, and lack long-term stability, and there is a need for a therapeutic approach that can effectively prevent, arrest, or ameliorate vision loss associated with this condition.
Innovation Solution
A recombinant adeno-associated virus (rAAV) is used, carrying a nucleic acid sequence encoding a normal NPHP5 protein or fragment thereof, under the control of regulatory sequences that express the protein in photoreceptor cells, administered with a pharmaceutically acceptable carrier to target specific areas of the retina for therapeutic intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional therapeutic interventions are initiated after the onset of photoreceptor degeneration, then some treatment effect may be achieved, but the outcomes are modest and transient due to limited window for corrective intervention
Solution Approach 1:
The patent applies preliminary action by administering AAV-mediated gene therapy before the onset of significant photoreceptor degeneration, during the pre-symptomatic or early symptomatic phase. This timing allows the therapeutic NPHP5 protein to be expressed before critical retinal structures are damaged, thereby achieving more reliable and durable outcomes rather than attempting to reverse established degeneration.
2Reliability
If gene therapy is administered to restore NPHP5 protein function, then photoreceptor function may be rescued, but long-term stability of the treatment effect is not yet established
Solution Approach 1:
The patent employs continuity of useful action through the use of AAV vectors that provide long-term expression of the NPHP5 protein. The viral vector integrates into the host genome or establishes persistent expression, ensuring continuous production of functional protein over extended periods. This continuous action is crucial for maintaining photoreceptor function and structural integrity throughout the treatment duration, addressing the concern about long-term stability.
3Productivity
If therapeutic intervention is delayed until after degeneration has progressed, then the disease course may be naturally monitored, but the interval between intervention and assessment is extended, reducing productivity of research translation
Solution Approach 1:
The patent implements feedback mechanisms through established disease metrics and monitoring protocols that allow rapid assessment of treatment effects. By using objective measures such as electroretinographic traces, imaging studies, and functional testing, the research team can quickly evaluate whether the gene therapy is producing the desired outcomes. This feedback loop enables accelerated translation from basic research to clinical application, reducing the time interval between intervention and assessment while maintaining rigorous scientific validation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The treatment effectively rescues photoreceptor function and preserves retinal structure for at least two years, as demonstrated by electroretinographic traces and imaging studies, showing significant improvement and stability in retinal function and structure in NPHP5 mutant dogs.
Implementation Method 1
The rAAV includes an AAV capsid protein and a nucleic acid sequence encoding a normal NPHP5 protein, or fragment thereof, under the control of regulatory sequences which express the NPHP5 in the photoreceptor cells of a subject
Data Source
AI summary
Described herein are methods of preventing, arresting progression of or ameliorating vision loss and other conditions associated with Leber congenital amaurosis (LCA) in a subject. The methods include administering to said subject an effective concentration of a composition comprising a recombinant adeno-associated virus (AAV) carrying a nucleic acid sequence encoding a normal NPHP5 protein, or fragment thereof, under the control of regulatory sequences which express the NPHP5 protein in the photoreceptor cells of the subject, and a pharmaceutically acceptable carrier.